mrn

The COVID-19 Spike Protein mRNA, responsible for expressing the COVID-19 spike protein, is crucial for evaluating RNA delivery, translation efficiency, and cell viability. Positioned on the membrane surface, this spike protein facilitates virus entry into cells by binding to host cell membrane receptors and promoting membrane fusion. It serves as a significant action site for neutralizing antibodies and represents a primary focus in vaccine development [1].

CD19 CAR mRNA is designed to express the CD19 chimeric antigen receptor (CAR) protein, pivotal in chimeric antigen receptor T cell (CAR-CD19) immunotherapy. This receptor targets CD19, a membrane antigen crucial for B cell proliferation, differentiation, activation, and antibody synthesis, playing a significant role in promoting BCR signal transduction.

CD19 car mRNA-LNP, a lipid nanoparticle (LNP) encapsulating CD19 car mRNA, is instrumental in assessing RNA delivery, translation efficacy, and cell viability among other applications. This compound is pivotal for chimeric antigen receptor T cell immunotherapy (CAR-CD19), leveraging the CD19 molecule - a critical membrane antigen expressed by B cells (i.e., leukocyte differentiation antigen) that plays a significant role in their proliferation, differentiation, activation, and antibody production, as well as enhancing BCR signal transduction [1] [2].

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) formulated with the novel coronavirus pneumonia spike protein, positioned on the membrane surface. It is designed for applications such as RNA delivery, translation efficiency, and cell viability assessment. This spike protein facilitates the COVID-19 virus's entry into host cells by binding to cell membrane receptors and enabling membrane fusion, making it a critical focal point for host neutralizing antibodies and vaccine development [1].

eGFP mRNA-LNP is a lipid nanoparticle encapsulating eGFP mRNA, designed to evaluate RNA delivery, translation efficiency, and cell viability. Upon cell internalization, it expresses Enhanced Green Fluorescent Protein (eGFP), enabling detection through fluorescence microscopy or flow cytometry [1].

mRNA-Encapsulating Lipid Excipient 1 (Compound 2), a thiocarbamate-based ionizable lipid, serves as an excipient in the formulation of mRNA-encapsulating lipid nanoparticles [1].

Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) comprising Firefly luciferase mRNA, designed for assays involving RNA delivery, translation efficiency, and cell viability. It serves as a bioluminescent reporter gene for studies on gene regulation and function. Once inside cells, Firefly luciferase mRNA produces firefly luciferase protein, making it suitable for promoter activity assays or dual-luciferase complementation experiments. Common luciferases include Firefly luciferase and Renilla luciferase.

PFM03 is an endonuclease inhibitor that specifically blocks Mre11 and is also able to reduce MRN endonuclease activity by 98%, blocking hMRN-mediated endonucleotomy and nuclear exocytosis processes on the protein-binding end of the 5 ' and 3 ' chains.

Mirin is a Mre11-Rad50-Nbs1 (MRN) complex inhibitor that inhibits MRN-dependent ATM activation without affecting ATM protein kinase activity. It also inhibits Mre11-associated exonuclease activity, thereby disrupting DNA double-strand break repair.Mirin induces cell cycle arrest in G1 phase.

(Z)-Mirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity.